Mental Health of COVID-19 Patients—A Cross-Sectional Survey in Saudi Arabia

Hasan Saeed Alamri 1,*, Wesam F. Mousa 2, Abdullah Algarni 3, Shehata F. Megahid 4,5,*, Ali Al Bshabshe 4,*, Nada N. Alshehri 1,*, Dalal M. Bashah 6, Roaa Alosaimi 7,*, Ahlam Alshehri 6, Awad Alsamghan 4 and Abdullah Alsabaani 4

Abstract: Background: This study aims to investigate the mental health of COVID-19 patients in Saudi Arabia. Method: A cross-sectional study was carried out targeting confirmed cases of COVID-19 in Saudi Arabia. Due to travel and time constraints as well as the accessibility of patients, cases were included from East Jeddah Hospital, King Abdulaziz Hospital, and the Oncology Center in Jeddah. The data were collected using a predesigned self-administered questionnaire. The questionnaire addressed COVID-19 cases, personal data, medical history, smoking, traveling abroad, and work-related conditions. Additionally, data regarding contact level with COVID-19 cases were considered. The mental health statuses of the patients were assessed using a validated Arabic version of the Hospital Anxiety and Depression (HAD) scale. The study included 261 COVID-19 patients whose ages ranged from 18 to 65 years. Results: The survey findings revealed that 13% of COVID-19 patients had a borderline level of anxiety, 26.8% were considered anxiety cases, while 60.2% were normal. The findings also revealed that 29.9% had a borderline level of depression, 18.4% were considered depression cases, while 51.7% were normal. Conclusions: This study concluded that COVID-19 patients experience anxiety and depression, and as the COVID-19 epidemic continues to spread, the results of the study are particularly useful in developing a strategy to psychologically support COVID-19 patients.

Keywords: mental health; COVID-19; psychological status; anxiety and depression

1. Introduction

Almost 180 countries were affected by the outbreak of Coronavirus Disease 2019 (COVID-19) since its first detection in Wuhan, China, in December 2019 [1,2]. The World Health Organization (WHO) stated that the outbreak created a global public health emergency [3]. According to the WHO [4], the estimated global mortality rate is 3.4%, but the death rates differ between countries and age groups. The COVID-19 pandemic has not only challenged the world’s supply chains and health care systems but also affected the mental health of individuals [5]. The pandemic brought a halt to the hustle and bustle of modern society by imposing lockdowns, which prevented social interactions. The pan-
demic certainly gave rise to anxiety, fear, and depression with respect to the management of disease and spread of infection [6].

A study conducted by Li [7] investigated the prevalence and predictors of general psychiatric disorders during COVID-19 in the United Kingdom. The study’s findings suggested that people who contracted the virus can experience or develop general psychiatric disorders and tend to feel lonely. The study found that women and young children are considered at high risk of developing general psychiatric disorders and loneliness whereas having jobs and partners were considered protective factors. Another study conducted by Xiang [8] found that people with confirmed or suspected cases of COVID-19 might experience fear of the virus while those in quarantine may experience loneliness, anger, and boredom. Additionally, symptoms of infection such as fever, cough, hypoxia, and body aches as well as the adverse effects of treatment such as insomnia due to corticosteroids can lead to extreme anxiety and mental distress. Wu et al. [9] studied the mental health of the global population, in particular of health care workers, noninfectious chronic disease patients, COVID-19 patients, and quarantined persons. They retrieved 66 studies, including 221,970 participants in their meta-analysis. The overall pooled prevalence of depression, anxiety, distress, and insomnia was 31.4%, 31.9%, 41.1%, and 37.9%, respectively. Noninfectious chronic disease patients, quarantined persons, and COVID-19 patients were at higher risk for depression ($p < 0.01$) and anxiety ($p < 0.01$) than other populations. The general population and nonmedical staff were at lower risk for distress than other populations ($p < 0.01$). Physicians, nurses, and nonmedical staff showed a higher prevalence of insomnia ($p < 0.01$) than other populations.

Other pandemics that have emerged in past years, not only COVID-19, have also left a psychological impact on individuals. A study conducted by Ji [10] found psychological disorders such as obsession–compulsion, hostility, phobic anxiety, paranoid ideation, and anxiety among Ebola survivors. When Severe Acute Respiratory Syndrome (SARS) was first detected, in its early phase, a range of psychiatric morbidities were reported which included continuous depression, panic attacks, anxiety, delirium, and even suicide [8]. It is also worth mentioning that studies performed after the SARS outbreaks showed high rates of anxiety and depression in hospitalized patients [10,11].

Most medical research has been directed at treating fatal respiratory complications, but many patients face psychological obstacles, mainly anxiety and depression [8]. Both of these mental illnesses have considerable impacts on patients infected with this novel, potentially fatal virus. This may be due to fear of the disease itself, loneliness, or worries about family property [7,12]. Apart from fear of contracting the illness itself and from the effects of social isolation on mental health, which lead to anxiety and depression, two other possible factors could add to psychological stress of a disease: the first is when the virus directly affects the central nervous system [13], and the second occurs indirectly, by triggering the immune system and developing “cytokine storms” [14]. In a recent systematic review and meta-analysis that assessed the incidence of depression and anxiety in COVID-19 patients, Leigh-Hunt [15] stated that 45% of COVID-19 patients experienced depression while 47% of patients experienced anxiety. Furthermore, it was suggested that older age and exposure to episodes of low oxygen saturation are additional factors correlated with patients being anxious and depressed, since it was determined that older COVID-19 patients are at increased risk of death and that oxygen saturation is a key indicator in evaluating the severity of the disease [16]. Previous reports showed that females are prone to developing high levels of anxiety and depression [14]. Meanwhile, education level, marital status, having children, pregnancy, smoking, or chronic health conditions may contribute to the mental distress among COVID-19 patients [17] and need to be individually studied. Anxiety and depression are related to lengthier hospitalization and worse outcomes in several diseases [18,19].

Research into depression and anxiety experienced among COVID-19 patients in Saudi Arabia is essential, given that no previous study has been performed in this area. This importance stems from our expectation that the psychological complications of COVID-19 may
persist for a long time after recovery. Although we do not have sufficient information about the course of psychological complications as a consequence of infection with COVID-19, studies of previous coronavirus epidemics showed the persistence of psychiatric symptoms and disorders after recovery [20,21]. As an example, a systematic review examined psychiatric disorders in patients hospitalized for severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS). It assessed the prevalence of mental illness 3 to 46 months after recovery from infection (six studies, \( n > 500 \) cases) [20]. The point prevalence of anxiety, depressive, and posttraumatic stress disorders were 15%, 15%, and 32%, respectively.

This systematic review also examined psychiatric symptoms in survivors of the 2003 SARS and 2012 MERS epidemics (40 studies, \( n > 1300 \) hospitalized cases); follow-up occurred 2 months to 12 years after recovery from acute infection [22]. The most common symptom was a frequent recall of traumatic memories, which occurred in 30 percent of patients. Other relatively common symptoms included anxiety; depressed mood; fatigue; irritability; insomnia; and impairments of attention, concentration, and memory. Furthermore, social functioning and role functioning were each impaired among survivors when compared with the general population. Longer-term psychiatric outcomes also included stigma from health care professionals, families, friends, and the general public. The prevalence of long-term psychiatric illness secondary to COVID-19 may be higher than that observed after the SARS and MERS epidemics due to differences in treatments for the viral diseases and the epidemics’ social contexts [23]. For example, the economic crisis caused by the COVID-19 pandemic has surpassed the economic adversity imposed by prior coronavirus epidemics, and the social disruption appears more significant due to its much wider geographical reach. Accordingly, prompt anticipation of mental illness is highly significant in improving outcomes [1]. Therefore, the objective of this study is to determine the mental health statuses of COVID-19 patients if they experience depression and anxiety so that a strategy to support them psychologically can be devised by the health care system.

2. Materials and Methods
2.1. Study Design and Sample

A hospital-based cross-sectional study was conducted, targeting COVID-19 patients in Saudi Arabia aged 18 years or more. The treatment policy for COVID-19 cases followed in Saudi Arabia at the time of this study was to hospitalize moderate to severe cases in patients, who have high-risk factors such as obesity, diabetes, or hypertension. As for patients without symptoms or mild symptoms, they were simply instructed to isolate themselves in their homes. Since we did not have the means to contact COVID-19 patients in their homes, only hospitalized patients were recruited for this study. COVID-19 patients admitted to East Jeddah Hospital, King Abdulaziz Hospital, and the Oncology Center in Jeddah from 1 August to 15 September 2020 were included in this study. The researchers collected the data using a predesigned electronic self-administered questionnaire after intensive literature review and expert consultation. A panel of 5 consultants reviewed the questionnaire items independently, and conflict regarding any item was resolved by consensus first and then by voting. The questionnaire inquired about personal data, medical history, smoking, traveling abroad, and work-related conditions. Additionally, data regarding contact level with COVID-19 cases were considered.

The patient’s mental status was assessed using a validated Arabic version of the Hospital Anxiety and Depression (HAD) scale [24,25]. The Hospital Anxiety and Depression Scale (HADS) was devised 30 years ago by Zigmond and Snaith to measure anxiety and depression in a general medical population of patients. The HAD is short and takes a few minutes to complete while waiting to see the doctor. The HAD uses a 4-point response scale, 0–3, according to the severity of anxiety and depression. The depression domain is measured by seven items, and another seven items measure the anxiety domain. The total score for each domain ranges from 0–21 points. In both domain, cases with scores of
0–7 points are considered normal, cases with 8–10 points are considered to have a borderline abnormality, while scores 11–21 are assessed as cases of anxiety or depression depending on the domain scored. The study included 261 COVID-19 patients whose ages ranged from 18 to 65 years with a mean age of 38.6 ± 10.8 years old. The majority of patients were females (161) and males made up the minority (100).

Before starting the survey, the participants were informed about the study’s aims and personal data protection. They were asked to sign an informed consent form to participate. The study was conducted following the Declaration of Helsinki. It was approved by the King Khalid University Research Ethics Committee (approval number: ECM#2020-237-HAPO-06-B-001) and the Research Ethical Committee at General Directorate of Health Affair’s-Asir Region, Saudi Arabia.

2.2. Data Analysis

After the data were extracted, they were revised, coded, and fed to statistical software IBM SPSS version 22 (SPSS Inc., Chicago, IL, USA). All statistical analysis was performed using two-tailed tests. A p-value of less than 0.05 was considered statistically significant. Regarding the HAD, all items’ discrete scores were calculated for the depression and anxiety domains separately and categorized with reference to the cutoff points provided above in the Study Design and Sample section. Descriptive analysis based on the frequency and percentage distributions was performed for all variables, including demographic data, work data, and factors associated with risk among COVID-19 cases. Cross tabulation was used to assess the distribution of depression and anxiety statuses according to their personal and work-related data. Relations were tested using the exact probability test due to small frequencies. A line graph was used to assess the association between anxiety and depression scores based on Pearson’s correlation analysis.

3. Results

Table 1 demonstrates the study included 261 COVID-19 patients whose ages ranged from 18 to 65 years with a mean age of 38.6 ± 10.8 years old. The majority of patients were females, 161 (61.7%). Regarding educational level, 165 (63.2%) patients were university graduates. As for the work sector, 98 (37.5%) patients were not working, 82 (31.4%) worked in the governmental sector, while 66 (25.3%) worked in the private sector. Regarding income, 120 (46%) cases reported a monthly income of less than 5000 SR and only 16 (6.1%) had an income of 20,000 SR or more. Overall, 167 (64%) patients were married and 57.9% had children.

| Personal Data          | No | %   |
|------------------------|----|-----|
| Gender                 |    |     |
| Male                   | 100| 38.3%|
| Female                 | 161| 61.7%|
| Age in years           |    |     |
| <25 years              | 45 | 17.2%|
| 25–34                  | 85 | 32.6%|
| 35–44                  | 79 | 30.3%|
| 45–54                  | 42 | 16.1%|
| 55+                    | 10 | 3.8% |
| Nationality            |    |     |
| Saudi                  | 220| 84.3%|
| Non-Saudi              | 41 | 15.7%|
| Educational level      |    |     |
| Below secondary        | 37 | 14.2%|
| Secondary              | 59 | 22.6%|
| University/more        | 165| 63.2%|
| Work                   |    |     |
| Not working            | 98 | 37.5%|
| Governmental sector    | 82 | 31.4%|
| Private sector         | 66 | 25.3%|
| Military sector        | 15 | 5.7% |
Table 1. Cont.

| Personal Data     | No | %   |
|-------------------|----|-----|
| Monthly income    |    |     |
| <5000 SR          | 120| 46.0%|
| 5000–10,000       | 54 | 20.7%|
| 10,000–20,000     | 71 | 27.2%|
| >20,000 SR        | 16 | 6.1% |
| Marital status    |    |     |
| Single            | 82 | 31.4%|
| Married           | 167| 64.0%|
| Divorced/widow    | 12 | 4.6% |
| Children          |    |     |
| No children       | 110| 42.1%|
| 1–2               | 44 | 16.9%|
| 3–5               | 75 | 28.7%|
| 6+                | 32 | 12.3%|

Table 2 demonstrates the risk factors for COVID-19 infection among study patients. Overall, 72 (27.6%) patients were smokers, 23% had a chronic health condition, and 8 females were pregnant (7.4%). Traveling abroad was reported among 8 cases (3.1%), and 121 patients (46.4%) were in contact with COVID cases. Regarding quarantine days, quarantine exceeded 22 days among 78 (40.8%) cases while 17 (8.9%) cases were quarantined for one week.

Table 2. Risk factors for COVID-19 infection among study patients, Saudi Arabia.

| Risk Factors with COVID-19 | No | %   |
|---------------------------|----|-----|
| Pregnant                  |    |     |
| Yes                       | 8  | 7.4%|
| No                        | 100| 92.6%|
| Smoking                   |    |     |
| Nonsmoker                 | 189| 72.4%|
| Ex-smoker                 | 34 | 13.0%|
| Current smoker            | 38 | 14.6%|
| Chronic health conditions |    |     |
| None                      | 201| 77.0%|
| D.M.                      | 19 | 7.3% |
| HTN                       | 23 | 8.8% |
| Allergic/autoimmune diseases | 27 | 10.3%|
| Chronic cardiac conditions | 6  | 2.3% |
| Psychological conditions  | 6  | 2.3% |
| Renal conditions          | 4  | 1.5% |
| Hypothyroidism            | 3  | 1.1% |
| Was abroad within the last three months |    |     |
| Yes                       | 8  | 3.1% |
| No                        | 253| 96.9%|
| Contact with a confirmed COVID-19 case |    |     |
| Yes                       | 121| 46.4%|
| No                        | 140| 53.6%|
| Days in Hospital          |    |     |
| 1–7                       | 17 | 8.9% |
| 8–14                      | 63 | 33.0%|
| 15–21                     | 33 | 17.3%|
| 22+                       | 78 | 40.8%|

Table 3 illustrates anxiety and depression among COVID-19 patients in Saudi Arabia. Exactly 38.7% of the patients felt restless if they have to be on the move, 38.3% of the patients could not sit at ease or feel relaxed, 29.3% of them felt high levels of tension or felt wound up, and 26.4% had worrying thoughts. Among the cases of anxiety, 34 (13%) people had a borderline abnormal level of anxiety while 70 (26.8%) had confirmed cases of anxiety. Exactly 57.4% of the cases could not enjoy the things they used to enjoy, 50.6% could not enjoy a good book, or radio or TV program, 38.3% of the patients lost interest in their appearance, and 36.4% hardly looked forward to enjoying things. Among the cases of
depression, 78 (29.9%) people had borderline depression while 48 (18.4%) had confirmed cases of depression.

| Anxiety Items                                      | No  | %    |
|---------------------------------------------------|-----|------|
| **I feel tense or wound up.**                     |     |      |
| Not at all                                        | 102 | 39.1%|
| From time to time, occasionally                   | 83  | 31.8%|
| A lot of the time                                 | 41  | 15.7%|
| Most of the time                                  | 35  | 13.4%|
| **I get a sort of frightened feeling as if something awful is about to happen** | | |
| Not at all                                        | 126 | 48.8%|
| A little, but it does not worry me                 | 84  | 32.6%|
| Yes, but not too badly                             | 32  | 12.4%|
| Very definitely and quite badly                    | 16  | 6.2% |
| **Worrying thoughts go through my mind**          |     |      |
| Only occasionally                                  | 137 | 52.5%|
| From time to time, but not too often               | 55  | 21.1%|
| A lot of the time                                  | 39  | 14.9%|
| A great deal of the time                          | 30  | 11.5%|
| **I can sit at ease and feel relaxed**            |     |      |
| Definitely                                        | 90  | 34.5%|
| Usually                                           | 71  | 27.2%|
| Not Often                                         | 79  | 30.3%|
| Not at all                                        | 21  | 8.0% |
| **I get a sort of frightened feeling like butterflies in the stomach** | | |
| Not at all                                        | 126 | 48.3%|
| Occasionally                                      | 89  | 34.1%|
| Quite Often                                       | 16  | 6.1% |
| Very Often                                        | 30  | 11.5%|
| **I feel restless if I have to be on the move**   |     |      |
| Not at all                                        | 46  | 17.6%|
| Not very much                                     | 114 | 43.7%|
| Quite a lot                                       | 45  | 17.2%|
| Very much indeed                                  | 56  | 21.5%|
| **I get sudden feelings of panic**                |     |      |
| Not at all                                        | 136 | 52.1%|
| Not very often                                    | 64  | 24.5%|
| Quite often                                       | 43  | 16.5%|
| Very often indeed                                 | 18  | 6.9% |
| **Anxiety level**                                 |     |      |
| Normal (0–7)                                      | 157 | 60.2%|
| Borderline (8–10)                                 | 34  | 13.0%|
| Abnormal (11–21)                                  | 70  | 26.8%|

| Depression Items                                   |     |      |
|----------------------------------------------------|-----|------|
| **I still enjoy the things I used to enjoy**       |     |      |
| Definitely as much                                 | 18  | 6.9% |
| Not quite so much                                  | 93  | 35.6%|
| Only a little                                      | 34  | 13.0%|
| Hardly at all                                      | 116 | 44.4%|
| **I can laugh and see the funny side of things**   |     |      |
| As much as I always could                          | 186 | 71.3%|
| Not quite so much now                              | 53  | 20.3%|
| Definitely not so much now                         | 16  | 6.1% |
| Not at all                                         | 6   | 2.3% |
| **I feel cheerful**                                |     |      |
| Most of the time                                   | 69  | 26.4%|
| Sometimes                                          | 100 | 38.3%|
| Not often                                          | 68  | 26.1%|
| Not at all                                         | 24  | 9.2% |
Table 3. Cont.

| Anxiety Items                          | No | %   |
|----------------------------------------|----|-----|
| I feel as if I am slowed down           |    |     |
| Not at all                             | 125| 47.9%|
| Sometimes                              | 80 | 30.7%|
| Very often                             | 25 | 9.6% |
| Nearly all the time                    | 31 | 11.9%|
| I have lost interest in my appearance  |    |     |
| I take just as much care as ever       | 110| 42.1%|
| I may not take quite as much care      | 51 | 19.5%|
| I don’t take as much care as I should  | 88 | 33.7%|
| Definitely                             | 12 | 4.6% |
| I look forward with enjoyment to things|    |     |
| As much as I ever did                  | 114| 43.7%|
| Rather less than I used to             | 52 | 19.9%|
| Definitely less than I used to         | 78 | 29.9%|
| Hardly at all                          | 17 | 6.5% |
| I can enjoy a good book or radio or T.V. program | | |
| Often                                  | 92 | 35.2%|
| Sometimes                              | 37 | 14.2%|
| Not often                              | 85 | 32.6%|
| Very seldom                            | 47 | 18.0%|
| Depression                             |    |     |
| Normal                                 | 135| 51.7%|
| Borderline                             | 78 | 29.9%|
| Abnormal                               | 48 | 18.4%|

Table 4 demonstrates the distribution of COVID-19 cases for anxiety and depression according to their bio-demographic data. Anxiety was significantly higher among females (34.8 vs. 14%, respectively; \( p = 0.001 \)). Additionally, 38.8% of cases aged 25–34 years had anxiety compared to 20% of those aged 55+ years (\( p = 0.027 \)). Considering nationality, anxiety was detected among 30% of Saudi cases compared to 9.8% of non-Saudi cases (\( p = 0.007 \)). Exactly 42.2% of patients who were health care workers had anxiety compared to 23.6% of non-health care workers (\( p = 0.010 \)). Additionally, 35.5% of cases with no children had anxiety compared to 21.9% of those who had six children or more (\( p = 0.048 \)). Depression was detected among 42.2% of females compared to 9% of males, with a reported statistical significance (\( p = 0.002 \)). Additionally, 24.3% of patients with low levels of education were depressed compared to 3.4% of patients with secondary school levels of education (\( p = 0.003 \)). Figure 1 demonstrates the Distribution of study cases according to anxiety and depression statuses, about 14% of cases have both depression and anxiety. Regarding the correlation between a patient’s depression and anxiety (Figure 2), it was clear that there is a significant positive intermediate correlation between depression and anxiety scores among males and females (\( r = 0.60 \) for males, \( r = 0.67 \) for females, and overall \( r = 0.65 \)).

Table 4. Distribution of COVID-19 patients with anxiety and depression according to their bio-demographic data.

| Factors          | Anxiety No | Anxiety % | p-Value | Depression No | Depression % | p-Value |
|------------------|------------|-----------|---------|---------------|--------------|---------|
| Gender           | Male       |           |         |               |              |         |
|                  | 14         | 14.0%     | 0.001 * | 9             | 9.0%         | 0.002 * |
|                  | Female     | 56        | 34.8%   | 39            | 24.2%        |         |
|                  | <25 years  | 12        | 26.7%   | 7             | 15.6%        |         |
|                  | 25–34      | 33        | 38.8%   | 19            | 22.4%        |         |
|                  | 35–44      | 17        | 21.5%   | 15            | 19.0%        | 0.027 * |
|                  | 45–54      | 6         | 14.3%   | 4             | 9.5%         | 0.374   |
|                  | 55+        | 2         | 20.0%   | 3             | 30.0%        |         |
| Age in years     |            |           |         |               |              |         |
|                  |            |           |         |               |              |         |
### Table 4. Cont.

| Factors                      | Anxiety No | %   | p-Value | Depression No | %   | p-Value |
|------------------------------|------------|-----|---------|---------------|-----|---------|
| Nationality                  | Saudi      | 66  | 30.0%   | 43            | 19.5%| 0.265   |
|                             | Non-Saudi  | 4   | 9.8%    | 5             | 12.2%|         |
| Educational level            | Below      | 8   | 21.6%   | 9             | 24.3%|         |
|                             | secondary  |     |         |               |      |         |
|                             | Secondary  | 10  | 16.9%   | 2             | 3.4% | 0.003 * |
|                             | University/more | 52 | 31.5% | 37 | 22.4% |         |
| Health care worker           | Yes        | 19  | 42.2%   | 12            | 26.7%| 0.115   |
|                             | No         | 51  | 23.6%   | 36            | 16.7%|         |
| Marital status               | Single     | 28  | 34.1%   | 16            | 19.5%|         |
|                             | Married    | 39  | 23.4%   | 28            | 16.8%| 0.342   |
|                             | Divorced/widow | 3 | 25.0% | 4 | 33.3% |         |
| Children                     | No children| 39  | 35.5%   | 23            | 20.9%|         |
|                             | 1–2        | 7   | 15.9%   | 11            | 25.0%| 0.288   |
|                             | 3–5        | 17  | 22.7%   | 10            | 13.3%|         |
|                             | 6+         | 7   | 21.9%   | 4             | 12.5%|         |
| Pregnant                     | Yes        | 4   | 50.0%   | 2             | 25.0%| 0.879   |
|                             | No         | 28  | 28.0%   | 23            | 23.0%|         |
| Smoking                      | Nonsmoker  | 53  | 28.0%   | 35            | 18.5%| 0.426   |
|                             | Ex-smoker  | 6   | 17.6%   | 4             | 11.8%|         |
|                             | Current smoker | 11 | 28.9% | 9 | 23.7% |         |
| Chronic health conditions    | No         | 56  | 27.9%   | 35            | 17.4%| 0.455   |
|                             | Yes        | 14  | 23.3%   | 13            | 21.7%|         |

*p*: Exact probability test. *p* < 0.05 (significant).

---

**Figure 1.** Distribution of study cases according to anxiety and depression statuses.
4. Discussion

This study aimed to investigate the mental health conditions of COVID-19 patients using a cross-sectional survey that evaluates the occurrence of psychological disorders such as depression, anxiety, and stress. The study’s objective was to determine the mental health statuses of COVID-19 patients if they experience depression and anxiety so that a strategy to psychologically support COVID-19 patients can be devised by the health care system. The number of confirmed COVID-19 cases is still steeply rising worldwide. According to the severity of the illness, patients are either hospitalized, admitted in isolated wards, or self-quarantined at home [26]. The study survey revealed that 13% of COVID-19 patients had a borderline level of anxiety, 26.8% had clear cases of anxiety, while 60.2% were normal. Regarding depression, while 29.9% had a borderline level of depression, 18.4% had clear cases of depression, and 51.7% were normal. These anxiety and depressive disorders may be related to the deviation in daily life, low levels of understanding of the disease, and fear of death [27,28]. These results highlight the need to pay attention to patients’ mental statuses and to provide support to relieve their anxiety and depression [29]. The study findings also suggest that the levels of anxiety are significantly higher among females than males (34.8% vs. 14%, respectively; \( p = 0.001 \)). This finding is supported by another study that stated that females are prone to developing higher levels of anxiety and depression [14]. This finding raises the question of whether we can assume that COVID-19 plays a role in this differential finding or perhaps there are social reasons for the differences in anxiety and depression between the genders. Further investigations are needed to clarify this issue.

A recent systematic review and meta-analysis by Leigh-Hunt [15], which assessed the incidence of depression and anxiety in COVID-19 patients, stated that 45% of COVID-19 patients experienced depression while 47% of patients experienced anxiety, which is significantly higher than the results of the survey in this study. This discrepancy may be related to the difference in time at which the data were collected and the differences in nationality with consequent differences in attitudes and religious beliefs, as the majority of the included patients in Leigh-Hunt’s review were from China. As the COVID-19 epidemic continues to spread, our study results help to develop a psychological strategy to support COVID-19 patients.
5. Conclusions

Depression and anxiety are very common among COVID-19 patients in Saudi Arabia. Policymakers in the health care system should apply the findings discussed within this research to implement necessary actions to alleviate the burdens of the COVID-19 pandemic on mental health. It is also essential to consider how the increased need for mental health services will likely continue in the long term, even though new cases and deaths due to COVID-19 will eventually subside. Additionally, health care professionals and females are at high risk and should be given priority when implementing such interventions. Furthermore, a community health care center should be made accessible to people who experience high levels of psychological disorders.

6. Study Limitations

The present study was conducted in Saudi Arabia, and generalizing the results to other areas of the world is not feasible. Additionally, the data were only collected once upon admission; thus, the investigators were unable to follow patients’ psychological changes over time. Moreover, individuals with COVID-19 who had no symptoms or mild disorders (i.e., who did not require hospitalization) were not included in our study. This study cannot determine a causal relationship between anxiety or depression and the sociodemographic variables as this requires a large, multicenter study that is beyond the scope of this research. Therefore, further multicenter studies are required to investigate the previous queries.

Author Contributions: Conceptualization, H.S.A.; Formal analysis, H.S.A.; Funding acquisition, A.A. (Abdullah Alsabaani); Investigation, H.S.A.; Methodology, H.S.A., W.F.M., A.A. (Abdullah Algarni), S.F.M., A.A.B., N.N.A., D.M.B., R.A., A.A. (Ahlam Alshehri) and A.A. (Awad Alsamghan); Project administration, H.S.A.; Writing—original draft, H.S.A., W.F.M., A.A. (Abdullah Algarni), S.F.M., A.A.B., N.N.A., D.M.B., R.A., A.A. (Ahlam Alshehri) and A.A. (Awad Alsamghan); Writing—review & editing, H.S.A. and A.A. (Abdullah Alsabaani). All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Institute of Research and Counselling Studies at King Khalid University, Abha, Saudi Arabia (grant number #4-N-20/21).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by King Khalid University Research Ethics Committee (approval number: ECM#2020-237-HAPO-06-B-001) and the Research Ethical Committee at General Di-rectorate of Health Affairs-Aseer Region, Saudi Arabia.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data set used and analyzed during the study is available from the corresponding author upon reasonable request.

Acknowledgments: The authors are thankful to the Institute of Research and Consulting Studies at King Khalid University for supporting this research through grant number #4-N-20/21.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Heymann, D.L. Data sharing and outbreaks: Best practice exemplified. *Lancet* 2020, 395, 469–470. [CrossRef]
2. Vara, V. Coronavirus Outbreak: The Countries Affected. 2020. Available online: https://www.pharmaceutical-technology.com/features/coronavirusoutbreak-the-countries-affected/ (accessed on 16 January 2021).
3. World Health Organization. Mental Health and Psychosocial Considerations during the COVID-19 Outbreak; World Health Organization: Geneva, Switzerland, 2020.
4. WHO. Coronavirus Disease (COVID-19) Situation Report—46, 2020b. 2019. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-COVID-19.pdf?sfvrsn=96b04adf_2 (accessed on 16 January 2021).
5. Ebrahim, S.H.; Ahmed, Q.A.; Gozzer, E.; Schlagenhauf, P.; Memish, Z.A. Covid-19 and community mitigation strategies in a pandemic. *BMJ* 2020, 368. [CrossRef]
6. Zhou, X.; Snoswell, C.L.; Harding, L.E.; Bambling, M.; Edirippulige, S.; Bai, X.; Smith, A.C. The role of telehealth in reducing the mental health burden from COVID-19. *Telemed. J. E Health* 2020, 26, 377–379. [CrossRef] [PubMed]
7. Li, L.Z.; Wang, S. Prevalence and predictors of general psychiatric disorders and loneliness during COVID-19 in the United Kingdom. Psychiatry Res. Sep. 2020, 291, 113267. [CrossRef] [PubMed]

8. Xiang, Y.T.; Yang, Y.; Li, W.; Zhang, L.; Zhang, Q.; Cheung, T.; Ng, C.H. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry 2020, 7, 228–229. [CrossRef]

9. Wu, T.; Jia, X.; Shi, H.; Niu, J.; Yin, X.; Xie, J.; Wang, X. Prevalence of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis. J. Affect. Disord. 2021, 281, 91–98. [CrossRef] [PubMed]

10. Ji, D.; Ji, Y.J.; Duan, X.Z.; Li, W.G.; Sun, Z.Q.; Song, X.A.; Meng, Y.-H.; Tang, H.-M.; Chu, F.; Niu, X.-X.; et al. Prevalence of psychological symptoms among Ebola survivors and healthcare workers during the 2014–2015 Ebola outbreak in Sierra Leone: A cross-sectional study. Oncotarget 2017, 8, 12784–12791. [CrossRef] [PubMed]

11. Wu, P.; Fang, Y.; Guian, Z.; Fan, B.; Kong, J.; Yao, Z.; Liu, X.; Fuller, C.J.; Susser, E.; Lu, J.; et al. The psychological impact of the SARS epidemic on hospital employees in China: Exposure, risk perception, and altruistic acceptance of risk. Canadian journal of psychiatry. Rev. Can. Psychiatry 2009, 54, 302–311. [CrossRef] [PubMed]

12. Banerjee, D.; Rai, M. Social isolation in Covid-19: The impact of loneliness. Int. J. Soc. Psychiatry 2020, 66, 525–527. [CrossRef] [PubMed]

13. Hua, Y.; Chena, Y.; Zhenga, Y.; Youa, C.; Tanb, J.; Hub, L.; Zhanga, Z.; Dinga, L. Factors related to mental health of inpatients with COVID-19 in Wuhan, China. Brain Behav. Immun. 2020, 89, 587–593. [CrossRef] [PubMed]

14. Jiawen, D.; Fangwen, Z.; Wenteng, H.; Zachary, S.; Chi, Y.W.; Oswin, C.; Emma, H.; Kang, Z.Q. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: A meta-analysis. Ann. N. Y. Acad. Sci. 2020. [CrossRef]

15. Leigh-Hunt, N.; Bagguley, D.; Bash, K.; Turner, V.; Turnbull, S.; Valtorta, N.; Caan, W. An overview of systematic reviews on the public health consequences of social isolation and loneliness. Public Health 2019, 152, 157–171. [CrossRef]

16. Kong, X.; Zheng, K.; Tang, M.; Kong, F.; Zhou, J.; Diao, L.; Wu, S.; Jiao, P.; Su, T.; Dong, Y. Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19. MedRxiv 2020. [CrossRef]

17. Polikandrioti, M.; Goudevenos, J.; Michalis, L.K.; Koutelekos, J.; Kyristi, H.; Tzialas, D.; Eliasf, M. Factors associated with depression and anxiety of hospitalized patients with heart failure. Hell. J. Cardiol. 2015, 56, 26–35. [PubMed]

18. DiMatteo, M.R.; Lepper, H.S.; Crogan, T.W. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000, 160, 2101–2107. [CrossRef]

19. Shoa, S.; Naderan, M.; Aghjani, M.; Sahimi-Izadian, E.; Hosseini-Araghi, N.; Khorgami, Z. Prevalence and Determinants of Depression and Anxiety Symptoms in Patients. Oman Med. J. 2016, 31, 176–181. [CrossRef] [PubMed]

20. Galea, S.; Merchant, R.M.; Lurie, N. The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention. JAMA Intern. Med. 2020, 180, 817. [CrossRef] [PubMed]

21. Holmes, E.A.; O’Connor, R.C.; Perry, V.; Tracey, I.; Wessely, S.; Arseneault, L.; Ballard, C.; Christensen, H.; Silver, R.C.; Everall, I.; et al. Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. Lancet Psychiatry 2020, 7, 547. [CrossRef]

22. Rogers, J.P.; Chesney, E.; Oliver, D.; Pollak, T.A.; McGuire, P.; Fusar-Poli, P.; Zandi, M.S.; Lewis, G.; David, A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020, 7, 611. [CrossRef]

23. Sommer, I.E.; Bakker, P.R. What can psychiatrists learn from SARS and MERS outbreaks? Lancet Psychiatry 2020, 7, 565. [CrossRef]

24. Malasi, T.H.; Mirza, I.A.; El-Islam, M.F. Validation of the Hospital Anxiety and Depression Scale in Arab patients. Acta Psychiatr. Scand. 1991, 84, 323–326. [CrossRef]

25. El Rufaie, O.E.; Absood, G.H.; Abou-Saleh, M.T. Retesting the validity of the Arabic version of the hospital anxiety and depression (HAD) scale in primary health care. Soc. Psychiatry Psychiatr. Epidemiol. 1995, 30, 26–31. [CrossRef] [PubMed]

26. Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72,314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. [CrossRef]

27. Wang, C.; Pan, R.; Wan, X.Y.; Tan, Y.; Xu, L.; McIntyre, R.S.; Choo, F.N.; Tran, B.; Ho, R.; Sharma, V.K.; et al. A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav. Immun. 2020, 87, 40–48. [CrossRef]

28. Wang, C.; Pan, R.; Wan, X.Y.; Tan, Y.; Xu, L.; Ho, C.S.; Ho, R.C. Immediate psychological responses and associated factors during the initial stage of the 2019 novel coronavirus disease (COVID-19) epidemic among the general population in China. Brain Behav. Immun. 2020, 17, 1272. [CrossRef]

29. Aghagoli, G.; Marin, B.G.; Katchur, N.J.; Chaves-Sell, F.; Asaad, W.F.; Murphy, S.A. Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. Neurocrit. Care 2020. [CrossRef]